Every S-3 that Pulmatrix, Inc. (PULM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow PULM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PULM filings page.
Pulmatrix, Inc. registers for resale by RCM Eos PIPE HOLDINGS, LLC up to an aggregate of 491,607 shares of Common Stock, issuable upon conversion of Series B preferred stock and as dividends. The selling stockholder may not sell the shares until the registration statement is effective. Pulmatrix will receive no proceeds from resales; it will pay registration expenses, while the selling stockholder bears any commissions and discounts.
The registered shares include 454,546 conversion shares and up to 37,061 dividend shares. The preferred shares carry a $2.20 per-share conversion price and cumulative dividends at 8% per annum, payable in common stock. Pulmatrix states that the maximum registered issuance represents approximately 13% of common shares outstanding and could substantially dilute existing stockholders; 3,652,285 common shares were issued and outstanding as of September 29, 2026. A 9.99% beneficial ownership limit restricts conversion by the holder and its affiliates.
Pulmatrix, Inc. is registering the resale of up to 490,910 shares of common stock, consisting of 454,546 Conversion Shares issuable upon conversion of 1,000 shares of Series B Convertible Preferred Stock at a $2.20 conversion price and up to 36,364 Dividend Shares issuable as an 8% annual stock dividend over one year. These shares were originally issued in a March 26, 2026 private placement and are being registered to satisfy resale obligations under a Securities Purchase Agreement. The company will not receive proceeds from any resale, though it bears registration expenses. As of May 27, 2026, Pulmatrix had 3,652,285 common shares outstanding; the shares covered here represent about 13% of that amount and could cause substantial dilution. A 9.99% beneficial ownership limitation caps conversions at any time, and any remaining Series B shares automatically convert after the earlier of one year from issuance or closing of the proposed merger with Eos SENOLYTIX, subject to those limits.
Pulmatrix, Inc. is registering the resale of up to 490,910 shares of Common Stock (including up to 36,364 Dividend Shares) issuable upon conversion of 1,000 Series B Convertible Preferred Shares sold in a private placement.
The Preferred Shares convert at a $2.20 conversion price and carry an 8% per annum dividend payable in Common Stock. The selling stockholder listed is RCM Eos PIPE HOLDINGS, LLC; proceeds from sales will go to the selling stockholder, not the company. The shares covered represent approximately 13% of Common Stock outstanding as of the prospectus; shares outstanding were 3,652,285 as of May 27, 2026.